AR126185A1 - ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS CD47 AND PD-L1 - Google Patents
ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS CD47 AND PD-L1Info
- Publication number
- AR126185A1 AR126185A1 ARP220101614A ARP220101614A AR126185A1 AR 126185 A1 AR126185 A1 AR 126185A1 AR P220101614 A ARP220101614 A AR P220101614A AR P220101614 A ARP220101614 A AR P220101614A AR 126185 A1 AR126185 A1 AR 126185A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antibody
- specifically binds
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 10
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 10
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 10
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 10
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 18
- 239000012634 fragment Substances 0.000 abstract 11
- 239000000427 antigen Substances 0.000 abstract 10
- 102000036639 antigens Human genes 0.000 abstract 10
- 108091007433 antigens Proteins 0.000 abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo biespecífico que se une específicamente a CD47 y PD-L1. La invención se refiere además a un ácido nucleico que codifica dicho anticuerpo biespecífico, un vector de expresión, una célula huésped para producir dicho anticuerpo biespecífico y un método para producir dicha célula, composiciones farmacéuticas que comprenden el anticuerpo biespecífico de acuerdo con la invención, composiciones farmacéuticas que comprenden el anticuerpo biespecífico de acuerdo con la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por CD47 y PD-L1, uso del anticuerpo biespecífico o composiciones farmacéuticas del mismo para tratar enfermedades o trastornos mediados por CD47 y PD-L1, y el uso del anticuerpo biespecífico de acuerdo con la invención y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por CD47 y PD-L1. Reivindicación 1: Un anticuerpo biespecífico aislado que se une específicamente a CD47 y PD-L1 e incluye: 1) un primer fragmento de unión al antígeno que se une específicamente a CD47 e incluye: (a) un dominio variable de cadena pesada que comprende: (i) CDR1 con la secuencia de aminoácidos de la SEQ ID Nº 1, (ii) CDR2 con la secuencia de aminoácidos de la SEQ ID Nº 2, (iii) CDR3 con la secuencia de aminoácidos de la SEQ ID Nº 3; y (b) un dominio variable de cadena liviana común que comprende: (i) CDR1 con la secuencia de aminoácidos de la SEQ ID Nº 4, (ii) CDR2 con la secuencia de aminoácidos de la SEQ ID Nº 5, (iii) CDR3 con la secuencia de aminoácidos de la SEQ ID Nº 6; 2) un segundo fragmento de unión al antígeno que se une específicamente a PD-L1 e incluye: (a) un dominio variable de cadena pesada que comprende: (i) CDR1 con la secuencia de aminoácidos de la SEQ ID Nº 7, (ii) CDR2 con la secuencia de aminoácidos de la SEQ ID Nº 8, (iii) CDR3 con la secuencia de aminoácidos de la SEQ ID Nº 9; y (b) un dominio variable de cadena liviana común que comprende: (i) CDR1 con la secuencia de aminoácidos de la SEQ ID Nº 4, (ii) CDR2 con la secuencia de aminoácidos de la SEQ ID Nº 5, (iii) CDR3 con la secuencia de aminoácidos de la SEQ ID Nº 6. Reivindicación 2: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, caracterizado porque el primer fragmento de unión al antígeno que se une específicamente a CD47 es un Fab unido a un monómero del fragmento Fc. Reivindicación 3: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, caracterizado porque el segundo fragmento de unión al antígeno que se une específicamente a PD-L1 es un Fab unido a un monómero del fragmento Fc. Reivindicación 4: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, caracterizado porque el anticuerpo es un anticuerpo IgG de longitud completa. Reivindicación 7: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde el dominio variable de cadena pesada del primer fragmento de unión al antígeno que se une específicamente a CD47 comprende la secuencia de aminoácidos de la SEQ ID Nº 22. Reivindicación 8: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde el dominio variable de cadena pesada del segundo fragmento de unión al antígeno que se une específicamente a PD-L1 comprende la secuencia de aminoácidos de la SEQ ID Nº 24. Reivindicación 9: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde el dominio variable de la cadena liviana común para el primer y segundo fragmentos de unión al antígeno comprende la secuencia de aminoácidos de la SEQ ID Nº 23. Reivindicación 11: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde la cadena pesada del primer fragmento de unión al antígeno que se une específicamente a CD47 comprende la secuencia de aminoácidos de la SEQ ID Nº 25. Reivindicación 12: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde la cadena pesada del segundo fragmento de unión al antígeno que se une específicamente a PD-L1 comprende la secuencia de aminoácidos de la SEQ ID Nº 27. Reivindicación 13: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, en donde la cadena liviana común para el primer y segundo fragmentos de unión al antígeno comprende la secuencia de aminoácidos de la SEQ ID Nº 26. Reivindicación 15: El anticuerpo biespecífico aislado de acuerdo con la reivindicación 1, que es un anticuerpo bivalente.The present invention relates to the field of biotechnology and medicine, in particular to a bispecific antibody that specifically binds to CD47 and PD-L1. The invention further relates to a nucleic acid encoding said bispecific antibody, an expression vector, a host cell for producing said bispecific antibody and a method for producing said cell, pharmaceutical compositions comprising the bispecific antibody according to the invention, compositions pharmaceutical compositions comprising the bispecific antibody according to the invention and other therapeutically active compounds, methods of treating diseases or disorders mediated by CD47 and PD-L1, use of the bispecific antibody or pharmaceutical compositions thereof to treat diseases or disorders mediated by CD47 and PD-L1 -L1, and the use of the bispecific antibody according to the invention and other therapeutically active compounds to treat diseases or disorders mediated by CD47 and PD-L1. Claim 1: An isolated bispecific antibody that specifically binds to CD47 and PD-L1 and includes: 1) a first antigen binding fragment that specifically binds to CD47 and includes: (a) a heavy chain variable domain comprising: (i) CDR1 with the amino acid sequence of SEQ ID No. 1, (ii) CDR2 with the amino acid sequence of SEQ ID No. 2, (iii) CDR3 with the amino acid sequence of SEQ ID No. 3; and (b) a common light chain variable domain comprising: (i) CDR1 with the amino acid sequence of SEQ ID NO: 4, (ii) CDR2 with the amino acid sequence of SEQ ID NO: 5, (iii) CDR3 with the amino acid sequence of SEQ ID NO: 6; 2) a second antigen binding fragment that specifically binds to PD-L1 and includes: (a) a heavy chain variable domain comprising: (i) CDR1 with the amino acid sequence of SEQ ID NO: 7, (ii) ) CDR2 with the amino acid sequence of SEQ ID No. 8, (iii) CDR3 with the amino acid sequence of SEQ ID No. 9; and (b) a common light chain variable domain comprising: (i) CDR1 with the amino acid sequence of SEQ ID NO: 4, (ii) CDR2 with the amino acid sequence of SEQ ID NO: 5, (iii) CDR3 with the amino acid sequence of SEQ ID NO: 6. Claim 2: The isolated bispecific antibody according to claim 1, characterized in that the first antigen binding fragment that specifically binds CD47 is a Fab linked to a monomer of the fragment Fc. Claim 3: The isolated bispecific antibody according to claim 1, characterized in that the second antigen binding fragment that specifically binds PD-L1 is a Fab linked to a monomer of the Fc fragment. Claim 4: The isolated bispecific antibody according to claim 1, characterized in that the antibody is a full-length IgG antibody. Claim 7: The isolated bispecific antibody according to claim 1, wherein the heavy chain variable domain of the first antigen binding fragment that specifically binds CD47 comprises the amino acid sequence of SEQ ID NO: 22. Claim 8: The isolated bispecific antibody according to claim 1, wherein the heavy chain variable domain of the second antigen binding fragment that specifically binds PD-L1 comprises the amino acid sequence of SEQ ID NO: 24. Claim 9: The Isolated bispecific antibody according to claim 1, wherein the common light chain variable domain for the first and second antigen binding fragments comprises the amino acid sequence of SEQ ID NO: 23. Claim 11: The bispecific antibody isolated from according to claim 1, wherein the heavy chain of the first antigen binding fragment that specifically binds CD47 comprises the amino acid sequence of SEQ ID NO: 25. Claim 12: The isolated bispecific antibody according to claim 1, wherein the heavy chain of the second antigen binding fragment that specifically binds PD-L1 comprises the amino acid sequence of SEQ ID NO: 27. Claim 13: The isolated bispecific antibody according to claim 1, wherein the chain Common light for the first and second antigen binding fragments comprises the amino acid sequence of SEQ ID NO: 26. Claim 15: The bispecific antibody isolated according to claim 1, which is a bivalent antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021118025A RU2815823C2 (en) | 2021-06-21 | Isolated bispecific antibody that specifically binds to cd47 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126185A1 true AR126185A1 (en) | 2023-09-27 |
Family
ID=84544589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101614A AR126185A1 (en) | 2021-06-21 | 2022-06-21 | ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS CD47 AND PD-L1 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4359445A1 (en) |
| CN (1) | CN117858904A (en) |
| AR (1) | AR126185A1 (en) |
| BR (1) | BR112023026982A2 (en) |
| CL (1) | CL2023003854A1 (en) |
| CO (1) | CO2023018165A2 (en) |
| CR (1) | CR20230612A (en) |
| EC (1) | ECSP23097121A (en) |
| MA (1) | MA63538A1 (en) |
| MX (1) | MX2024000266A (en) |
| PE (1) | PE20250352A1 (en) |
| TW (1) | TW202306998A (en) |
| WO (1) | WO2022271053A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2622097T3 (en) * | 2009-07-24 | 2017-07-05 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Procedure for the development of a liquid composition to be applied as a foam on the skin as well as a composition that can be applied topically |
| RU2665790C1 (en) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Monoclonal pd-l1 antibody |
| EA039662B1 (en) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
-
2022
- 2022-06-21 MA MA63538A patent/MA63538A1/en unknown
- 2022-06-21 AR ARP220101614A patent/AR126185A1/en unknown
- 2022-06-21 CN CN202280044514.XA patent/CN117858904A/en active Pending
- 2022-06-21 EP EP22828864.3A patent/EP4359445A1/en active Pending
- 2022-06-21 TW TW111123100A patent/TW202306998A/en unknown
- 2022-06-21 MX MX2024000266A patent/MX2024000266A/en unknown
- 2022-06-21 BR BR112023026982A patent/BR112023026982A2/en unknown
- 2022-06-21 PE PE2023003437A patent/PE20250352A1/en unknown
- 2022-06-21 WO PCT/RU2022/050195 patent/WO2022271053A1/en active Application Filing
- 2022-06-21 CR CR20230612A patent/CR20230612A/en unknown
-
2023
- 2023-12-21 CO CONC2023/0018165A patent/CO2023018165A2/en unknown
- 2023-12-21 CL CL2023003854A patent/CL2023003854A1/en unknown
- 2023-12-27 EC ECSENADI202397121A patent/ECSP23097121A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117858904A (en) | 2024-04-09 |
| EP4359445A1 (en) | 2024-05-01 |
| PE20250352A1 (en) | 2025-02-06 |
| CR20230612A (en) | 2024-07-29 |
| TW202306998A (en) | 2023-02-16 |
| MA63538A1 (en) | 2024-09-30 |
| CO2023018165A2 (en) | 2024-05-30 |
| WO2022271053A1 (en) | 2022-12-29 |
| BR112023026982A2 (en) | 2024-03-12 |
| CL2023003854A1 (en) | 2024-07-19 |
| MX2024000266A (en) | 2024-01-31 |
| ECSP23097121A (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (en) | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES | |
| AR112257A1 (en) | MULTI-SPECIFIC ANTIBODIES TARGETING HIV-1 GP120 AND HUMAN CD3, COMPOSITIONS THAT UNDERSTAND THEM, NUCLEIC ACID, RELATED VECTOR AND HOST CELL, METHOD TO PRODUCE THEM, METHOD TO DETECT THEM, METHOD OF DETECTING ANPOSITION OF KEYS1 AND EXPEDITED CD3 CELLS TO GP120 AND METHOD TO PRODUCE THEM | |
| JP2018516853A5 (en) | ||
| PE20220763A1 (en) | MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY | |
| PE20231851A1 (en) | PROTEINS THAT BIND TO NKG2D, CD16 AND CLEC12A | |
| WO2022083675A1 (en) | Monoclonal antibody used against various coronaviruses and application thereof | |
| AR109533A2 (en) | ANTI-FRACTALKINA ANTIBODIES OR A FRAGMENT OF UNION TO THE FKN OF THIS, COMPOSITIONS THAT INCLUDE IT AND METHODS TO TREAT INFLAMMATORY DISORDERS | |
| AR123480A1 (en) | THERAPEUTIC BINDING MOLECULES | |
| PE20230616A1 (en) | ANTIBODIES THAT BIND CD3 AND FOLR1 | |
| AR110755A1 (en) | BONE DIRECTED ANTIBODIES | |
| WO2020218951A3 (en) | Monoclonal antibody that binds specifically to gitr | |
| PE20240589A1 (en) | CD1a ANTIBODIES AND THEIR USE | |
| AR123306A1 (en) | FGFR3 ANTIBODIES AND METHODS OF USE | |
| JP2017523805A5 (en) | ||
| PE20240224A1 (en) | BISPECIFIC ANTI-TSPAN8/ANTI-CD3 ANTIBODY AND ANTI-TSPAN8 ANTIBODY | |
| AR124084A1 (en) | HEAVY CHAIN ANTIBODIES THAT BIND THE α-FOLATE RECEPTOR | |
| JP2015526071A (en) | Humanized form of monoclonal antibody against human GnRH receptor | |
| JPWO2022044573A5 (en) | ||
| KR20240031229A (en) | Antibodies for the treatment of alpha-synucleinopathy | |
| AR126185A1 (en) | ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS CD47 AND PD-L1 | |
| RU2016117140A (en) | TRANSPECIFIC ANTIBODIES AGAINST IL-17A, IL-17F AND ANOTHER INFLAMMATORY MOLECULE | |
| AR129472A1 (en) | ANTI-BCMA ANTIBODIES | |
| AR125219A1 (en) | MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF | |
| AR125040A1 (en) | ANTI-VISION CONSTRUCTS AND THEIR USES | |
| Gao et al. | A novel monospecific tetravalent IgG1-(scFv) 2 version shown enhanced neutralizing and Fc-mediated effector functions against SARS-CoV-2 |